SCHEMBL5044779

SCHEMBL5044779

CCC(C)NC(=O)c1cc(-c2csc(-c3ccc(OC)cc3)n2)n(CCOC)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
TP53 P04637 3/20 0.47
MAPK1 P28482 2/20 0.47
STAT1 P42224 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KLKB1 P03952 1/20 0.44
KDM4E B2RXH2 3/20 0.44
MAPT P10636 5/20 0.43
LMNA P02545 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CRHBP P24387 1/20 0.43
HTT P42858 1/20 0.43
CRHR2 Q13324 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5045092 0.95 ALDH1A1 (0.54) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL5039629 0.92 ALDH1A1 (0.49) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL5043851 0.91 SMN1; SMN2 (0.48) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL5047025 0.91 KLKB1 (0.49) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL5043787 0.88 ALDH1A1 (0.51) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL5043336 0.88 NPC1 (0.50) ALDH1A1SMN1; SMN2RAB9ANPC1TP53
SCHEMBL5044535 0.88 ALDH1A1 (0.53) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL5044983 0.86 CDC25A (0.44) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL5047785 0.86 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2RAB9ANPC1TP53
SCHEMBL5048681 0.85 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R ALDH1A1 959/4885HPGD 2000/4885SMN1; SMN2 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.